


**LISTING AND AMENDMENT OF THE CLAIMS**

1-31. (Canceled).

32. (Currently Amended) A method for treating an infection in a patient, comprising orally administering to a patient in need thereof a therapeutically effective amount of a food and/or dietetic composition comprising one or more sialyzed carbohydrates selected from the group consisting of disialyl-lacto-N-tetraose (DS-LNT), disialyl-lacto-N-neo-tetraose (DS-LNnT), glycomacropeptide (GMP), ganglioside G<sub>D1a</sub>, ganglioside G<sub>T1b</sub> and ganglioside G<sub>T1a</sub>, of formula I:



wherein:

Sia means a sialic acid or an O-acetyl-sialic acid derivative in an  $\alpha$  2-3 bond;

Gal means a galactose-monosaccharide unit;

HexNac means an N-acetylated galactosamine-monosaccharide unit or glucosamine-monosaccharide unit (GalNAc or GlcNAc);

Hex means a galactose-monosaccharide unit or glucose-monosaccharide unit (Gal or Glc);

C represents HHexNac or Hex or is absent;


n represents 1 to 50;

— wherein X is a first sialic acid or an O-acetyl-sialic acid derivative thereof, optionally having a second-sialic acid or an O-acetyl-sialic acid derivative bound to the first sialic acid or O-acetyl-sialic acid derivative in an  $\alpha$  2-3 bond, a phosphate group, a sulphate group, carboxyl group, or a monosaccharide having a phosphate group, sulphate group or carboxyl group;

— wherein only one of the residues X is present;

V is a) OH when n represents 1, b) a carbohydrate residue or c) a connecting point on a carrier T<sub>1</sub> with the proviso that when V represents b) a carbohydrate residue being a monosaccharide residue, an oligosaccharide residue or a polysaccharide residue or c) a carrier T<sub>1</sub>,

n means the number of the carbohydrate units of formula II that are each directly bound to this b) carbohydrate residue or c) carrier, and formula II is as follows:



and

wherein the sialyzed carbohydrate are in a form so that sia- $\alpha$ -2-3-residues of said sialyzed carbohydrates bind to pathogens; and

said sialyzed carbohydrates are incorporated in said food and/or dietetic composition.

33-35. (Canceled).

36. (Currently Amended) The method according to claim 32, wherein the ~~carbohydrate or~~ carbohydrates of formula I are administered in an amount of 1 mg per kg of body weight of said patient.


37. (Previously Presented) The method according to claim 32, wherein the patient has an infection of the gastrointestinal tract, blood system, respiratory passage, urogenital tract, or nasopharynx.

39-40. (Canceled).

41. (Previously Presented) The method of claim 32, wherein the patient has an infection of the gastrointestinal tract and the patient is human.

42. (Currently Amended) A food and/or a dietetic composition ~~composition in a form for oral administration comprising one or more~~ sialyzed ~~carbohydrate carbohydrates selected from the group consisting of disialyl-lacto-N-tetraose (DS-LNT), disialyl-lacto-N-neo-tetraose (DS-~~

L<sub>Nn</sub>T), glycomacropeptide (GMP), ganglioside G<sub>D1b</sub>, ganglioside G<sub>T1b</sub> and ganglioside G<sub>T1c</sub>, of formula I:



wherein;

Sia means a sialic acid or an O-acetyl-sialic acid derivative in an  $\alpha$  2-3 bond;

Gal means a galactose monosaccharide unit;

HexNac means an N-acetylated-galactosamine monosaccharide unit or glucosamine monosaccharide unit (GalNAc or GlcNAc);

Hex means a galactose monosaccharide unit or glucose monosaccharide unit (Gal or Glc);


C represents HexNac or Hex or is absent;

n represents 1 to 50;

— wherein X is a first sialic acid or an O-acetyl-sialic acid derivative thereof, optionally having a second sialic acid or an O-acetyl-sialic acid derivative bound to the first sialic acid or O-acetyl-sialic acid derivative in an  $\alpha$  2-3 bond, a phosphate group, a sulphate group, carboxyl group, or a monosaccharide having a phosphate group, sulphate group or carboxyl group;

— wherein only one of the residues X is present;

V is a) OH when n represents 1, b) a carbohydrate residue or c) a connecting point on a carrier T<sub>1</sub>, with the proviso that when V represents b) a carbohydrate residue being a monosaccharide residue, an oligosaccharide residue or a polysaccharide residue or c) a carrier T<sub>1</sub>; n means the number of the carbohydrate units of formula II that are each directly bound to this b) carbohydrate residue or c) carrier, and formula II is as follows:



and

~~wherein the sialyzed carbohydrate are in a form so that sia- $\alpha$ -2-3 residues of said sialyzed carbohydrates bind to pathogens; and~~

said sialyzed carbohydrates are incorporated in a food and/or dietetic composition.

43. (Previously Presented) The composition according to claim 42, further comprising an auxiliary agent, diluent, moisturizing agent, thickening agent, flavoring agent, sweetening agent, or carrier.

44-49. (Canceled).

50. (Currently Amended) The composition according to claim 42, wherein the composition is in a form selected from the group consisting of a beverage, baby formula, food supplement, infant formula, milk product, chocolate, cheese, sausage, meat product, anabolic food, and probe tube food administered via a feeding tube.

51. (Previously Presented) A method for treating a bacterial infection in a patient, comprising orally administering an effective amount of the composition according to claim 42 to said patient.

52. (Canceled).

53. (Previously Presented) The method according to claim 32, wherein the patient is a pregnant women, an infant, debilitated person, or an elderly person.

54. (New) The method according to claim 32, wherein said sialyzed carbohydrates are connected to a carrier.

55. (New) The method according to claim 54, wherein said carrier is selected from the group consisting of polymers, carbohydrates, glycolipids and gangliosides.

56. (New) The method according to claim 55, wherein said carrier is a biopolymer selected from the group consisting of peptides and proteins.

57. (New) The composition according to claim 42, wherein said sialyzed carbohydrates are connected to a carrier.

58. (New) The composition according to claim 57, wherein said carrier is selected from the group consisting of polymers, carbohydrates, glycolipids and gangliosides.

59. (New) The composition according to claim 58, wherein said carrier is a biopolymer selected from the group consisting of peptides and proteins.

60. (New) The method according to claim 32, wherein said food and/or dietetic composition is not human milk.

61. (New) The composition according to claim 42, wherein said food and/or dietetic composition is not human milk.